Tillotts Pharma AG
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
D'Haens, Geert
LOVE-CD, NCT02646683 / 2014-005376-29: A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the Study

Completed
4
260
Europe
vedolizumab, Entyvio
Geert D'Haens, Takeda
Crohn Disease
05/23
05/23
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
DIRECTCD, NCT06059989: InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease

Recruiting
3
158
Europe
Infliximab subcutaneous, Remsima 120mg solution s.c., Immunosuppressive Agents, 6-mercaptopurine 1-1.5 mg/kg oral, or, if already on oral azathioprine or thioguanine continuous dosing 2-2.5mg/kg, or 20mg once daily respectively, In case of adverse events or investigator's individual consideration, instead of thiopurine, methotrexate 15 mg/week s.c. (or oral) in combination with oral folic acid 5 mg/week
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Celltrion
Inflammatory Disease, Disease Crohn, Bowel Disease
06/25
12/25
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
DIVE-23, NCT06006039: The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.

Recruiting
N/A
40
Europe, Canada
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn´s Disease
01/26
11/26

Download Options